Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Now Rated “Hold” by Wall Street Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received an average recommendation of “Hold” from the twenty-three research firms that are presently covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, ten have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $20.98.

NTLA has been the subject of a number of analyst reports. Wolfe Research cut shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective for the company. in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. Citizens Jmp reissued a “market outperform” rating and set a $30.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Finally, Wedbush increased their price objective on Intellia Therapeutics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 9th.

Intellia Therapeutics Stock Performance

NTLA stock opened at $11.42 on Tuesday. The stock’s 50 day simple moving average is $11.98 and its 200 day simple moving average is $13.26. The company has a market cap of $1.60 billion, a P/E ratio of -3.40 and a beta of 1.82. Intellia Therapeutics has a fifty-two week low of $7.95 and a fifty-two week high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.80). Intellia Therapeutics had a negative net margin of 672.16% and a negative return on equity of 57.79%. The business had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same quarter last year, the firm posted ($0.98) EPS. Intellia Therapeutics’s revenue was down 46.4% compared to the same quarter last year. Equities analysts predict that Intellia Therapeutics will post -3.21 earnings per share for the current year.

Insider Buying and Selling at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. This represents a 2.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NTLA. Opaleye Management Inc. raised its stake in shares of Intellia Therapeutics by 2.0% during the 2nd quarter. Opaleye Management Inc. now owns 250,000 shares of the company’s stock worth $4,230,000 after purchasing an additional 5,000 shares during the period. Integrated Wealth Concepts LLC purchased a new position in shares of Intellia Therapeutics in the 2nd quarter worth about $34,000. Arizona State Retirement System grew its position in Intellia Therapeutics by 17.0% during the second quarter. Arizona State Retirement System now owns 35,356 shares of the company’s stock valued at $598,000 after buying an additional 5,131 shares during the period. Nykredit A S bought a new position in Intellia Therapeutics during the second quarter valued at about $33,000. Finally, Wellington Grp LLC increased its holdings in Intellia Therapeutics by 46.2% during the second quarter. Wellington Grp LLC now owns 67,688 shares of the company’s stock worth $1,145,000 after buying an additional 21,391 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a biotechnology company focused on developing curative treatments using CRISPR-based gene-editing technology. The company’s approach is designed to make targeted changes to disease-associated genes, including through in vivo therapies that edit genes directly inside the body.

Intellia’s pipeline includes NTLA-2001, an investigational treatment designed to address transthyretin amyloidosis by editing the TTR gene, and NTLA-2002, an investigational therapy targeting hereditary angioedema through editing of the KLKB1 gene.